Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer.

Current liquid biopsy assays lack sufficient sensitivity to detect copy number loss, which limits the interrogation of critical tumor suppressor gene deletions during cancer progression and treatment. Here we describe a liquid biopsy assay with improved sensitivity for detection of copy number loss in blood samples with low levels of circulating tumor DNA, and demonstrate its utility by profiling PTEN , RB1 , and TP53 genetic loss in metastatic prostate cancer patients.
Competing Interests: XD, TZ, CD, PD, BK, SJ, and JY are stockholders of Predicine, Inc. PD, SJ, and JY are part of the leadership team of Predicine, Inc. FX, YZ, JD and YH are stockholders of Huidu Shanghai Medical Sciences, Ltd. MZ, RZ, and CL are stockholders of Laekna Therapeutics Shanghai Co., Ltd. YL and DW, and HL are stockholders of Shanghai Lide Biotech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Dong, Zheng, Zhang, Dai, Wang, Wang, Zhang, Long, Wen, Xie, Zhang, Huang, Dong, Liu, Du, King, Tan, Jia, Lu, Kohli, Wang and Yu.)